These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 10671405

  • 1. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD.
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [Abstract] [Full Text] [Related]

  • 2. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Inagaki T, Horiguchi J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr 01; 32(3):761-4. PubMed ID: 18201810
    [Abstract] [Full Text] [Related]

  • 3. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A.
    J Clin Psychiatry; 1997 Jul 01; 58(7):318-22. PubMed ID: 9269253
    [Abstract] [Full Text] [Related]

  • 4. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov 01; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 5. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
    Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J.
    J Clin Psychiatry; 1989 Jan 01; 50(1):26-7. PubMed ID: 2562952
    [Abstract] [Full Text] [Related]

  • 6. Ondansetron for tardive dyskinesia.
    Zullino DF, Eap CB, Voirol P.
    Am J Psychiatry; 2001 Apr 01; 158(4):657-8. PubMed ID: 11282718
    [No Abstract] [Full Text] [Related]

  • 7. Treating tardive dyskinesia with ondansetron.
    Sirota P, Mosheva T, Shabtai H, Korczyn AD.
    J Clin Psychopharmacol; 2001 Jun 01; 21(3):355-6. PubMed ID: 11386507
    [No Abstract] [Full Text] [Related]

  • 8. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
    Chaudhry IB, Husain N, Husain MO, Hallak J, Drake R, Kazmi A, Rahman Ru, Hamirani MM, Kiran T, Mehmood N, Stirling J, Dunn G, Deakin B.
    Trials; 2013 Apr 17; 14():101. PubMed ID: 23782463
    [Abstract] [Full Text] [Related]

  • 9. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS.
    Am J Psychiatry; 1998 Apr 17; 155(4):565-7. PubMed ID: 9546009
    [Abstract] [Full Text] [Related]

  • 10. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness.
    Arango C, Adami H, Sherr JD, Thaker GK, Carpenter WT.
    Am J Psychiatry; 1999 Jul 17; 156(7):1097-9. PubMed ID: 10401460
    [Abstract] [Full Text] [Related]

  • 11. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
    Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP.
    J Clin Psychiatry; 2004 May 17; 65(5):696-701. PubMed ID: 15163258
    [Abstract] [Full Text] [Related]

  • 12. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
    Chiu H, Lau J, Lam L, Shum P.
    Aust N Z J Psychiatry; 1993 Jun 17; 27(2):228-32. PubMed ID: 8103320
    [Abstract] [Full Text] [Related]

  • 13. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.
    Friedman JH.
    Mov Disord; 1994 May 17; 9(3):321-4. PubMed ID: 7913739
    [Abstract] [Full Text] [Related]

  • 14. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H, Hunt JI, Vitiello B, Simpson GM.
    J Clin Psychiatry; 1990 Aug 17; 51(8):319-21. PubMed ID: 1974249
    [Abstract] [Full Text] [Related]

  • 15. Treatment of clozapine-associated tardive dyskinesia.
    Lin CC, Bai YM, Chen JY, Wang YC, Liou YJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb 15; 32(2):599-600. PubMed ID: 17920744
    [No Abstract] [Full Text] [Related]

  • 16. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H, Bourgeois M.
    Encephale; 1996 Jun 15; 22 Spec No 2():45-7. PubMed ID: 8767042
    [Abstract] [Full Text] [Related]

  • 17. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC.
    Am J Psychiatry; 1999 Sep 15; 156(9):1374-9. PubMed ID: 10484947
    [Abstract] [Full Text] [Related]

  • 18. The role of ondansetron in the treatment of schizophrenia.
    Bennett AC, Vila TM.
    Ann Pharmacother; 2010 Sep 15; 44(7-8):1301-6. PubMed ID: 20516364
    [Abstract] [Full Text] [Related]

  • 19. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb 15; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 20. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM.
    Am J Psychiatry; 1998 Nov 15; 155(11):1521-8. PubMed ID: 9812112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.